AB Science plummets on second CHMP rejection for canine anticancer

The European Medicines Agency's committee for medicinal products for human use ( CHMP) has turned down AB Science's application to market pancreatic cancer drug Masiviera (masitinib) in Europe.

The European Medicines Agency's committee for medicinal products for human use ( CHMP) has turned down AB Science's application to market pancreatic cancer drug Masiviera (masitinib) in Europe.

This marks the second CHMP rejection for an AB Science cancer drug with the active ingredient masitinib in recent months....

More from Dermatological

More from Therapy Areas